Alluvi, formerly BI 4744, represents a significant development in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/